Figure 1
Effect of ICV injection of 2-AG (2µg), Picrotoxin (0.5µg) and their combination on percent of body weight cumulative food intake in neonatal layer type chickens (n=48). 2-AG: 2-Arachidonoylglycerol, selective CB1 receptors agonist, Picrotoxin: GABAA antagonist. Data are expressed as mean ± SEM. F and P value for within and between subject factors are as follows: Time, F(2,14)=93.45, p<0.001; 2-AG, F(l,42)=67.02, p<0.001; Picrotoxin, F(l,42)=0.01, p>0.05; Picrotoxin × 2-AG interaction, F(l,42)= 48.95, p<0.001. Different letters (a, b and c) indicate significant differences between treatments (p<0.001). The average body weight for each group was as follows: control, 62.14 g; 2-AG, 61.71 g; Picrotoxin, 61.48 g; 2-AG + Picrotoxin, 62.83 g.
Figure 2
Effect of ICV injection of2-AG (2µg), CGP54626 (21ng) and their combination on percent of body weight cumulative food intake in neonatal layer type chickens (n=48). 2-AG: 2-Arachidonoylglycerol, selective CB1 receptors agonist, CGP54626: GABAB antagonist. Data are expressed as mean ± SEM. F and P value for within and between subject factors are as follows: Time, F(2,69)=112.04, p<0.001; 2-AG, F(1,38)=39.51, p<0.001; CGP54626, F(1,38)=0.62, p>0.05; CGP54626×2-AG interaction, F(l,38)=0.08, p>0.05. Different letters (a and b) indicate significant differences between treatments (p<0.001). The average body weight for each group was as follows: control, 64.26 g; 2-AG, 63.92 g; CGP54626, 63.19 g; CGP54626 + 2-AG, 62.38 g.
Figure 3
Effect of ICV injection of CB65 (1.25µg), Picrotoxin (0.5µg) and their combination on percent of body weight cumulative food intake in neonatal layer type chickens (n=48). CB65: selective CB2 receptors agonist, Picrotoxin: GABAA antagonist. Data are expressed as mean ± SEM. F and P value for within and between subject factors are as follows: Time, F(2,81)=67.52, p<0.001; CB65, F(1,54)=76.01, p<0.001; Picrotoxin, F(1,54)=0.08, p>0.05; Picrotoxin × CB65interaction, F(1,54)=1. 36; p>0.05. Different letters (a and b) indicate significant differences between treatments (p<0.001). The average body weight for each group was as follows: control, 63.41 g; CB65, 63.75 g; Picrotoxin, 62.74 g; CB65 + Picrotoxin, 62.51 g.
Figure 4
Effect of ICV injection of CB65 (1.25µg), CGP54626 (21ng) and their combination on percent of body weight cumulative food intake in neonatal layer type chickens (n=48). CB65: selective CB2 receptors agonist, CGP54626: GABAB antagonist. Data are expressed as mean ± SEM. F and P value for within and between subject factors are as follows: Time, F(2,55)=124.13, p<0.001; CB65, F(1,26)=47.15, p<0.001; CGP54626, F(1,26)=0. 49, p>0.05; CGP54626× CB65interaction, F(1,26)=1. 27; p>0.05. Different letters (a and b) indicate significant differences between treatments (p<0.001). The average body weight for each group was as follows: control, 61.43 g; CB65, 62.04 g; CGP54626, 63.27 g; CB65 + CGP54626, 62.17 g.
Figure 5
Effect of ICV injection of Gaboxadol (0.2µg), SR141716A (6.25µg) and their combination on percent of body weight cumulative food intake in neonatal layer type chickens (n=48). Gaboxadol: GABAA agonist, SR141716A: selective CB1 receptors antagonist. Data are expressed as mean ± SEM. F and P value for within and between subject factors are as follows: Time, F(2,79)=56.27, p<0.001; Gaboxadol, F(1,53)=87.04, p<0.001; SR141716A, F(1,53)=0.31, p>0.05; SR141716A × Gaboxadol interaction, F(1,53)=65.93; p<0. 001. Different letters (a, b and c) indicate significant differences between treatments (p<0.001). The average body weight for each group was as follows: control, 64.26 g; Gaboxadol, 64.74 g; SR141716A, 64.06 g; Gaboxadol + SR141716A, 63.81 g.
Figure 6
Effect of ICV injection of Gaboxadol (0.2µg), AM630 (1.25µg) and their combination on percent of body weight cumulative food intake in neonatal layer type chickens (n=48). Gaboxadol: GABAA agonist, AM630: selective CB2 receptors antagonist. Data are expressed as mean ± SEM. F and P value for within and between subject factors are as follows: Time, F(2,17)=48.91, p<0.001; Gaboxadol, F(1,21)=38.12, p<0.001; AM630, F(1,21)=1.02, p>0.05; AM630 × Gaboxadol interaction, F(1,21)=2.37; p>0.05. Different letters (a and b) indicate significant differences between treatments (p<0.001). The average body weight for each group was as follows: control, 62.35 g; Gaboxadol, 61.96 g; AM630, 61.47 g; Gaboxadol + AM630, 62.94 g.
Figure 7
Effect of ICV injection of Baclofen (0.2µg), SR141716A (6.25µg) and their combination on percent of body weight cumulative food intake in neonatal layer type chickens (n=48). Baclofen: GABAB agonist, SR141716A: selective CB1 receptors antagonist. Data are expressed as mean ± SEM. F and P value for within and between subject factors are as follows: Time, F(2,83)=102.17, p<0.001; Baclofen, F(1,31)=46.73, p<0.001; SR141716A, F(1,31)=0.09, p>0.05; SR141716A × Baclofen interaction, F(1,31)=0.04; p>0.05. Different letters (a and b) indicate significant differences between treatments (p<0.001). The average body weight for each group was as follows: control, 64.11 g; baclofen, 64.26 g; SR141716A, 63.21 g; Baclofen + SR141716A, 62.75 g.
Figure 8
Effect of ICV injection of Baclofen (0.2µg), AM630 (1.25µg) and their combination on percent of body weight cumulative food intake in neonatal layer type chickens (n=48). Baclofen: GABAB agonist, AM630 (selective CB2 receptors antagonist). Data are expressed as mean ± SEM. F and P value for within and between subject factors are as follows: Time, F(2,65)=70.31, p<0.001; Baclofen, F(1,46)=63.01, p<0.001; AM630, F(1,46)=0.06, p>0.05; AM630 × Baclofen interaction, F(1,46)=0.83; p>0.05. Different letters (a and b) indicate significant differences between treatments (p<0.001). The average body weight for each group was as follows: control, 61.48 g; baclofen, 61.92 g; AM630, 63.19 g; baclofen + AM630, 62.38 g.